3 completed, 1 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Unknown 1 |
Follow NLS Pharmaceutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 NLS-2, Placebo - Narcolepsy Type 1, Narcolepsy With Cataplexy | Phase 3 | Unknown | NLS Pharmaceutics | 48 | 2024-07-15 | 2024-05-21 |
| An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy Mazindol - Narcolepsy With Cataplexy, Narcolepsy | Phase 2 | Completed | NLS Pharmaceutics | 52 | 2021-10-26 | 2023-03-13 |
| Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy mazindol extended release, Placebo - Narcolepsy, Excessive Daytime Sleepiness | Phase 2 | Completed | NLS Pharmaceutics | 67 | 2021-09-13 | 2022-08-12 |
| Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD) mazindol - Attention Deficit Disorder With Hyperactivity | Phase 2 | Completed | NLS Pharmaceutics | 84 | 2016-08-01 | 2017-04-06 |
Narcolepsy (3) · Attention Deficit Disorder with Hyperactivity (1) · Cataplexy (1) · Disorders of Excessive Somnolence (1)
Mazindol (2)
United States (3)
Carlos Camozzi, MD (2) · George Apostol, MD, MS (1)